^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
CTM-N2D
i
Other names: CTM-N2D, Haplo/ allogeneic NKG2DL-targetting chimeric antigen receptor-grafted γδ T cell therapy, Haploidentical/ allogeneic natural killer group 2D ligand CAR-γδT cell therapy, NKG2DL-targetting chimeric antigen receptor-grafted gamma delta T cell therapy, Adoptive Cell Transfer of NKG2DL-targetting Chimeric Antigen Receptor-grafted Gamma Delta T cell, CTMN2D, CTM N2D
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
CytoMed Therap
Drug class:
γδ TCR modulator, NKG2DL-targeted CAR-T immunotherapy
Related drugs:
over2years
ANGELICA: Allogeneic NKG2DL-targeting CAR γδ T Cells (CTM-N2D) in Advanced Cancers (clinicaltrials.gov)
P1, N=9, Not yet recruiting, CytoMed Therapeutics Pte Ltd
New P1 trial
|
NKG2D (killer cell lectin like receptor K1)
|
CTM-N2D
Share via
